New Drug Could Be the Beginning of the End for Sleeping Sickness
A breakthrough treatment brings the 2030 elimination goal within reach for a disease that has plagued sub-Saharan Africa for centuries
Sleeping sickness, formally known as human African trypanosomiasis, is transmitted by the bite of tsetse flies and can be fatal if untreated. The disease attacks the central nervous system, causing confusion, sleep disruption, and eventually death.
Previous treatments required complex hospital-based care, making them impractical in the remote rural areas where the disease is most prevalent. The new drug promises a simpler treatment regimen that could be administered in community health settings, dramatically expanding access.
The World Health Organization has targeted sleeping sickness for elimination as a public health problem by 2030. Case numbers have already dropped dramatically from tens of thousands per year to fewer than 1,000 annually, but the last mile of elimination has proven the hardest.
Analysis
Why This Matters
Sleeping sickness elimination would be one of the great public health achievements of the decade. A practical, field-deployable drug is the missing piece that could make the 2030 goal achievable.
Background
The disease has been a scourge of sub-Saharan Africa for centuries, with devastating epidemics in the 20th century killing hundreds of thousands. Decades of control efforts have reduced cases dramatically, but the tsetse fly vector remains widespread.
What to Watch
Regulatory approvals and deployment timelines for the new treatment, particularly in the Democratic Republic of Congo and other endemic countries where most remaining cases occur.